Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

agreement with Abbott regarding payment of the note on terms that will enable it to continue commercializing urokinase. Upon execution, the Company will hold full title to the asset including the remaining urokinase inventory and will receive 100% of proceeds generated from future sales. The Company expects to close this transaction in the second quarter of 2008.

Financial Results

Revenue for the fourth quarter ended December 31, 2007 rose to $2.7 million from $0.7 million for the fourth quarter ended December 31, 2006. Full year 2007 revenue increased to $8.4 million from $1.3 million for the full year 2006. Sales of urokinase, which ImaRx began commercializing in October 2006, drove the revenue increase for the most recent quarter and full year.

Net loss for the fourth quarter of 2007 was $2.2 million compared to net income of $10.7 million in the year ago period. This change was primarily a result of a $16.1 million gain on extinguishment of debt associated with the relinquishment of the recombinant thrombolytic drug assets to Abbott in the fourth quarter of 2006. Net loss per share attributable to common shareholders of $0.24 for the fourth quarter of 2007 was based on weighted average shares of approximately 9.1 million, compared to net income per share attributable to common shareholders of $3.94 in the fourth quarter of 2006 based on weighted average shares of approximately 2.6 million.

Net loss for the full year 2007 was $8.8 million compared to $0.7 million for the full year 2006. This change was primarily a result of a $16.1 million gain on extinguishment of debt associated with the relinquishment of the recombinant thrombolytic drug assets to Abbott in the fourth quarter of 2006, partially offset by increased sales of urokinase in 2007 over 2006. Net loss per share attributable to common shareholders of $3.16 for the full year 2007 was based on weighted average shares of approximately 5.9 million compared to a net loss per sha
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Sarasota, FL (PRWEB) November 17, 2014 ... novel point-of-care diagnostic tests – today announces its ... Control and Prevention’s (CDC) Get Smart About Antibiotics ... Antibiotics Week is a national campaign designed to ... local health departments, and non-profit and for-profit partners ...
(Date:11/18/2014)... November 17, 2014 Athena Signature Series: Turning ... Dr. Beverly Emerson, a professor in the Regulatory Biology Laboratory ... most recent discovery points to an “off switch” for drug ... and how her local research is making a global impact ... findings and then join host Cheryl K. Goodman, CEO of ...
(Date:11/18/2014)... 18, 2014 Brothers Josh and Bryce ... of PAWSitively Curing Cancer, Inc . in recognition ... (3) non-profit organization is dedicated to raising funds for ... to the University of Florida College of Veterinary ... Curing Cancer as the recipient of this vital funding. ...
(Date:11/18/2014)... Nov. 18, 2014 PDL BioPharma, Inc. (PDL) ... connection with the acquisition of Durata Therapeutics, Inc. by ... with the termination of PDL,s credit agreement with Durata, ... of $40 million, accrued interest, and prepayment and change ... a structured financing transaction with Durata in which PDL ...
Breaking Biology Technology:RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2
... ,, REYKJAVIK, Iceland , and SALT LAKE CITY, Utah , ... - U.S. Laboratories and Physicians ... , , , ... ARUP will offer deCODE,s DNA-based prostate cancer risk,assessment test to its clients nationwide. , ...
... television and computer screens could be brighter, clearer and ... by a team of researchers from Canada and the ... synthesis of a conjugated organic polymer--widely used as a ... solar cells--could mean more efficient, cheaper electronics. ...
... "Amira Pharmaceuticals, Inc. announced today that its FLAP (5-lipoxygenase-activating protein) program, which ... , , ... the program to Phase 2 studies, which explore the use of the Amira ... , , ...
Cached Biology Technology:ARUP Laboratories Ink Partnership to Offer deCODE ProstateCancer(TM) Test 2ARUP Laboratories Ink Partnership to Offer deCODE ProstateCancer(TM) Test 3ARUP Laboratories Ink Partnership to Offer deCODE ProstateCancer(TM) Test 4ARUP Laboratories Ink Partnership to Offer deCODE ProstateCancer(TM) Test 5Polymer synthesis could aid future electronics 2Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program 2
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/11/2014)... Nov. 11, 2014  Forensicon, Inc., a ... pleased to announce the promotion of Yaniv Schiff ... Digital Forensics. In Schiff,s new role as Director, he ... of digital forensics examiners and provide leadership within the ... - http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined ...
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the ... phase. In its first six months of existence, the Lab ... evidence support for local law enforcement. "Because our ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... in spring they will most likely buy flowering ornamental ... have shown that consumers favor plants that are already ... that can present multiple challenges for commercial growers. ... like bedding plants and perennials start growing crops far ...
... They challenge the mountain ranges of the Alps, the ... known about seamounts, the vast mountains hidden under the world,s ... scientists uncover the mystery of life on these submerged ... under threat. The bathymetry of our oceans ...
... decades scientists believed Neanderthals developed `modern, tools and ... , but new research from the University of ... adapt, innovate and evolve technology on their own. ... a half-century of conventional wisdom maintaining that Neanderthals ...
Cached Biology News:Rotating high-pressure sodium lamps provide flowering plants for spring markets 2Marine scientists unveil the mystery of life on undersea mountains 2Neanderthals more advanced than previously thought 2
8 different frozen tissues are mounted on positively charged glass slides...
Donor feline serum and plasma...
... These versatile vacuum cups provide flexible ... curved, or irregular surfaces. ,PFG: Flat ... Bellows cup ,PCG: Multiple Bellows cup ... from 25 to 200 mm , ...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
Biology Products: